CA2435967A1 - Reovirus pour le traitement de tumeurs malignes lymphoides - Google Patents

Reovirus pour le traitement de tumeurs malignes lymphoides Download PDF

Info

Publication number
CA2435967A1
CA2435967A1 CA002435967A CA2435967A CA2435967A1 CA 2435967 A1 CA2435967 A1 CA 2435967A1 CA 002435967 A CA002435967 A CA 002435967A CA 2435967 A CA2435967 A CA 2435967A CA 2435967 A1 CA2435967 A1 CA 2435967A1
Authority
CA
Canada
Prior art keywords
reovirus
cells
lymphoma
lymphoid
cell
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA002435967A
Other languages
English (en)
Inventor
Unknown
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Individual
Original Assignee
Oncolytics Biotech Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Oncolytics Biotech Inc filed Critical Oncolytics Biotech Inc
Priority to CA002435967A priority Critical patent/CA2435967A1/fr
Publication of CA2435967A1 publication Critical patent/CA2435967A1/fr
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/76—Viruses; Subviral particles; Bacteriophages
    • A61K35/765—Reovirus; Rotavirus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2720/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsRNA viruses
    • C12N2720/00011—Details
    • C12N2720/12011—Reoviridae
    • C12N2720/12032—Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Virology (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Microbiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CA002435967A 2003-07-25 2003-07-25 Reovirus pour le traitement de tumeurs malignes lymphoides Abandoned CA2435967A1 (fr)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CA002435967A CA2435967A1 (fr) 2003-07-25 2003-07-25 Reovirus pour le traitement de tumeurs malignes lymphoides

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CA002435967A CA2435967A1 (fr) 2003-07-25 2003-07-25 Reovirus pour le traitement de tumeurs malignes lymphoides

Publications (1)

Publication Number Publication Date
CA2435967A1 true CA2435967A1 (fr) 2005-01-25

Family

ID=34085272

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002435967A Abandoned CA2435967A1 (fr) 2003-07-25 2003-07-25 Reovirus pour le traitement de tumeurs malignes lymphoides

Country Status (1)

Country Link
CA (1) CA2435967A1 (fr)

Cited By (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007099401A3 (fr) * 2005-08-01 2008-03-13 Univ Technologies Int Reovirus attenue
US10369171B2 (en) 2007-03-13 2019-08-06 Virocure, Inc. Attenuated reoviruses for selection of cell populations
US10512662B2 (en) 2016-02-25 2019-12-24 Memorial Sloan Kettering Cancer Center Replication competent attenuated vaccinia viruses with deletion of thymidine kinase with and without the expression of human Flt3L or GM-CSF for cancer immunotherapy
US10548930B2 (en) 2015-04-17 2020-02-04 Memorial Sloan Kettering Cancer Center Use of MVA or MVAΔE3L as immunotherapeutic agents against solid tumors
US10639366B2 (en) 2015-02-25 2020-05-05 Memorial Sloan Kettering Cancer Center Use of inactivated nonreplicating modified vaccinia virus Ankara (MVA) as monoimmunotherapy or in combination with immune checkpoint blocking agents for solid tumors
US10668119B2 (en) 2005-08-01 2020-06-02 Virocure, Inc. Attenuated reovirus
US10736962B2 (en) 2016-02-25 2020-08-11 Memorial Sloan Kettering Cancer Center Recombinant MVA or MVADELE3L expressing human FLT3L and use thereof as immuno-therapeutic agents against solid tumors
US11242509B2 (en) 2017-05-12 2022-02-08 Memorial Sloan Kettering Cancer Center Vaccinia virus mutants useful for cancer immunotherapy

Cited By (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10668119B2 (en) 2005-08-01 2020-06-02 Virocure, Inc. Attenuated reovirus
US10260049B2 (en) 2005-08-01 2019-04-16 Virocure, Inc. Attenuated reovirus
WO2007099401A3 (fr) * 2005-08-01 2008-03-13 Univ Technologies Int Reovirus attenue
US10369171B2 (en) 2007-03-13 2019-08-06 Virocure, Inc. Attenuated reoviruses for selection of cell populations
US11426460B2 (en) 2015-02-25 2022-08-30 Memorial Sloan Kettering Cancer Center Use of inactivated nonreplicating modified vaccinia virus Ankara (MVA) as monoimmunotherapy or in combination with immune checkpoint blocking agents for solid tumors
US10639366B2 (en) 2015-02-25 2020-05-05 Memorial Sloan Kettering Cancer Center Use of inactivated nonreplicating modified vaccinia virus Ankara (MVA) as monoimmunotherapy or in combination with immune checkpoint blocking agents for solid tumors
US10548930B2 (en) 2015-04-17 2020-02-04 Memorial Sloan Kettering Cancer Center Use of MVA or MVAΔE3L as immunotherapeutic agents against solid tumors
US11253560B2 (en) 2015-04-17 2022-02-22 Memorial Sloan Kettering Cancer Center Use of MVA or MVAΔE3L as immunotherapeutic agents against solid tumors
US10736962B2 (en) 2016-02-25 2020-08-11 Memorial Sloan Kettering Cancer Center Recombinant MVA or MVADELE3L expressing human FLT3L and use thereof as immuno-therapeutic agents against solid tumors
US10765711B2 (en) 2016-02-25 2020-09-08 Memorial Sloan Kettering Cancer Center Replication competent attenuated vaccinia viruses with deletion of thymidine kinase with and without the expression of human FLT3L or GM-CSF for cancer immunotherapy
US11285209B2 (en) 2016-02-25 2022-03-29 Memorial Sloan Kettering Cancer Center Recombinant MVA or MVAΔE3L expressing human FLT3L and use thereof as immuno-therapeutic agents against solid tumors
US10512662B2 (en) 2016-02-25 2019-12-24 Memorial Sloan Kettering Cancer Center Replication competent attenuated vaccinia viruses with deletion of thymidine kinase with and without the expression of human Flt3L or GM-CSF for cancer immunotherapy
US11541087B2 (en) 2016-02-25 2023-01-03 Memorial Sloan Kettering Cancer Center Replication competent attenuated vaccinia viruses with deletion of thymidine kinase with and without the expression of human Flt3L or GM-CSF for cancer immunotherapy
US11986503B2 (en) 2016-02-25 2024-05-21 Memorial Sloan Kettering Cancer Center Replication competent attenuated vaccinia viruses with deletion of thymidine kinase with and without the expression of human Flt3L or GM-CSF for cancer immunotherapy
US11242509B2 (en) 2017-05-12 2022-02-08 Memorial Sloan Kettering Cancer Center Vaccinia virus mutants useful for cancer immunotherapy
US11884939B2 (en) 2017-05-12 2024-01-30 Memorial Sloan Kettering Cancer Center Vaccinia virus mutants useful for cancer immunotherapy

Similar Documents

Publication Publication Date Title
US7964187B2 (en) Sensitization of chemotherapeutic agent resistant neoplastic cells with a virus
AU782020B2 (en) Viruses for the treatment of cellular proliferative disorders
AU2002234453A1 (en) Sensitization of chemotherapeutic agent resistant neoplastic cells with reovirus
US20080038822A1 (en) Virus clearance of neoplastic cells from mixed cellular compositions
US20050214266A1 (en) Combination of transplantation and oncolytic virus treatment
US10668119B2 (en) Attenuated reovirus
CA2428805A1 (fr) Procede d'apport optimal d'un virus a une masse de tumeur solide
CA2435967A1 (fr) Reovirus pour le traitement de tumeurs malignes lymphoides
CA2436196A1 (fr) Virus oncolytique pour eliminer les cellules de tumeurs malignes lymphoides presentes dans des melanges de cellules
CA2617600A1 (fr) Reovirus attenue
AU2001258077A1 (en) Clearance of neoplastic cells from mixed cellular compositions using viruses
TW200404099A (en) The use of ribozymes in the detection of adventitious agents
US20020187465A1 (en) Viruses for the treatment of cellular proliferative disorders
US9365823B2 (en) Virus clearance of neoplastic cells from mixed cellular compositions
COFFEY et al. Patent 2388807 Summary
CA2605803A1 (fr) Clairance virale de cellules neoplastiques de compositions cellulaires mixtes

Legal Events

Date Code Title Description
FZDE Dead